Full-Time
Bioanalytical Scientist
Posted on 7/23/2024
Develops cell therapy for chronic kidney disease
Senior, Expert
Morrisville, NC, USA
ProKidney focuses on treating Chronic Kidney Disease (CKD) through a novel cell therapy called rilparencel. This therapy aims to preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which many patients currently rely on. ProKidney is in the late stages of clinical trials, and early results indicate that rilparencel may effectively maintain kidney function. Unlike other treatments, ProKidney specifically targets CKD, a condition affecting over 35 million adults in the U.S., and aims to fill a significant gap in available therapies. The company's goal is to provide a groundbreaking treatment that improves the quality of life for CKD patients and reduces their reliance on dialysis.
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
N/A